IN2014MN02132A - - Google Patents
Info
- Publication number
- IN2014MN02132A IN2014MN02132A IN2132MUN2014A IN2014MN02132A IN 2014MN02132 A IN2014MN02132 A IN 2014MN02132A IN 2132MUN2014 A IN2132MUN2014 A IN 2132MUN2014A IN 2014MN02132 A IN2014MN02132 A IN 2014MN02132A
- Authority
- IN
- India
- Prior art keywords
- proteins
- fgf21
- pharmaceutical compositions
- growth factor
- methods
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract 2
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 102000056713 human FGF21 Human genes 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
- Y10S530/814—Cellulose or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261658104P | 2012-06-11 | 2012-06-11 | |
| US201361777386P | 2013-03-12 | 2013-03-12 | |
| PCT/US2013/044190 WO2013188181A1 (en) | 2012-06-11 | 2013-06-05 | Fibroblast growth factor 21 proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02132A true IN2014MN02132A (OSRAM) | 2015-09-11 |
Family
ID=48670814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2132MUN2014 IN2014MN02132A (OSRAM) | 2012-06-11 | 2013-06-05 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8741841B2 (OSRAM) |
| EP (1) | EP2858662B1 (OSRAM) |
| JP (1) | JP6182600B2 (OSRAM) |
| KR (1) | KR20150006060A (OSRAM) |
| CN (1) | CN104394882B (OSRAM) |
| AR (1) | AR091216A1 (OSRAM) |
| AU (1) | AU2013274638A1 (OSRAM) |
| BR (1) | BR112014029966A2 (OSRAM) |
| CA (1) | CA2871145A1 (OSRAM) |
| CL (1) | CL2014003078A1 (OSRAM) |
| CO (1) | CO7151525A2 (OSRAM) |
| EA (1) | EA201492053A1 (OSRAM) |
| EC (1) | ECSP14030742A (OSRAM) |
| ES (1) | ES2644787T3 (OSRAM) |
| HK (1) | HK1203357A1 (OSRAM) |
| IL (1) | IL235832A0 (OSRAM) |
| IN (1) | IN2014MN02132A (OSRAM) |
| MX (1) | MX2014015257A (OSRAM) |
| PE (1) | PE20150201A1 (OSRAM) |
| PH (1) | PH12014502766A1 (OSRAM) |
| SG (1) | SG11201408095XA (OSRAM) |
| TN (1) | TN2014000439A1 (OSRAM) |
| TW (1) | TWI513705B (OSRAM) |
| WO (1) | WO2013188181A1 (OSRAM) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2068909B1 (en) | 2007-03-30 | 2012-04-25 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| EP2726511B1 (en) | 2011-07-01 | 2019-08-07 | NGM Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| CA2871656A1 (en) * | 2012-06-11 | 2013-12-19 | Eli Lilly And Company | Fibroblast growth factor 21 variants |
| EP2925775B1 (en) | 2012-11-28 | 2020-09-16 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| KR102724421B1 (ko) | 2012-12-27 | 2024-10-30 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법 |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| KR102178945B1 (ko) | 2013-10-28 | 2020-11-13 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 암 모델 및 관련 방법 |
| SI3097122T1 (sl) | 2014-01-24 | 2020-07-31 | Ngm Biopharmaceuticals, Inc. | Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo |
| BR112016017402A2 (pt) * | 2014-02-21 | 2017-10-17 | Medimmune Ltd | fusões anti-pcsk9~glp-1 e métodos para uso |
| US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| WO2015148708A1 (en) | 2014-03-25 | 2015-10-01 | Regeneron Pharmaceuticals, Inc. | Fgf21 receptor agonists and uses thereof |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| CA2951153A1 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| JP6308699B2 (ja) * | 2014-09-08 | 2018-04-11 | 国立大学法人大阪大学 | 脱髄疾患の予防又は治療剤 |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| KR102854572B1 (ko) | 2014-10-24 | 2025-09-02 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| KR20160088656A (ko) * | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| US11638745B2 (en) | 2015-05-20 | 2023-05-02 | University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education | Method to improve neurologic outcomes in temperature managed patients |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| KR102668200B1 (ko) | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| CN105348380B (zh) * | 2015-12-28 | 2019-03-01 | 江苏康缘瑞翱生物医药科技有限公司 | 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN106317226B (zh) | 2016-08-19 | 2017-09-05 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| EP3502143A4 (en) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| AU2017358289C1 (en) * | 2016-11-10 | 2025-05-08 | Yuhan Corporation | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |
| EP4470551A3 (en) | 2017-03-14 | 2025-02-26 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| US11560416B2 (en) | 2017-04-21 | 2023-01-24 | Yuhan Corporation | Method for producing dual function proteins and its derivatives |
| CN107385020A (zh) * | 2017-06-23 | 2017-11-24 | 西安医学院 | 瘦素在人重组fgf21蛋白活性检测中的应用 |
| EP3678686A1 (en) | 2017-09-08 | 2020-07-15 | Bristol-Myers Squibb Company | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| SMT202400277T1 (it) | 2017-12-22 | 2024-09-16 | Novartis Ag | Trattamento di disturbi metabolici con varianti di fgf21 |
| CN116098989A (zh) | 2018-02-08 | 2023-05-12 | 广东东阳光药业有限公司 | Fgf21变体、融合蛋白及其应用 |
| US12226451B2 (en) | 2018-07-03 | 2025-02-18 | Bristol-Myers Squibb Company | FGF-21 formulations |
| CN111195234B (zh) * | 2018-11-16 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组FGF21-Fc融合蛋白冻干粉制剂 |
| JP7664168B2 (ja) * | 2019-03-05 | 2025-04-17 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | ポリペプチド分子及びその適用 |
| PE20220500A1 (es) * | 2019-04-23 | 2022-04-07 | Lg Chemical Ltd | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 |
| AR122359A1 (es) | 2020-01-08 | 2022-09-07 | Bristol Myers Squibb Co | Formulaciones de fgf-21 conjugado |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| WO2022032187A1 (en) | 2020-08-07 | 2022-02-10 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| KR20220021207A (ko) | 2020-08-13 | 2022-02-22 | 주식회사 나이벡 | 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물 |
| KR102495299B1 (ko) * | 2020-11-03 | 2023-02-06 | 토드제약 주식회사 | Fgf21의 열탄력성을 이용한 fgf21 생산 방법 |
| WO2022115597A1 (en) | 2020-11-25 | 2022-06-02 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| BRPI0416683A (pt) | 2003-12-10 | 2007-01-30 | Lilly Co Eli | muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 |
| CA2565300A1 (en) | 2004-05-13 | 2005-12-01 | Eli Lilly And Company | Fgf-21 fusion proteins |
| EP2068909B1 (en) | 2007-03-30 | 2012-04-25 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| CH699521A2 (de) | 2008-09-09 | 2010-03-15 | Rotorcraft Ag | Streckwerk für eine Strickmaschine. |
| KR101651703B1 (ko) | 2008-10-10 | 2016-08-26 | 암젠 인크 | Ｆｇｆ21 돌연변이체 및 이의 용도 |
| WO2010065439A1 (en) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| EP2389190B1 (en) | 2009-01-23 | 2018-09-19 | Novo Nordisk A/S | Fgf21 derivatives with albumin binder a-b-c-d-e- and their use |
| WO2010129600A2 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| UY38740A (es) | 2009-05-05 | 2020-12-31 | Amgen Inc | Mutantes de fgf21 y usos del mismo |
| WO2011154349A2 (en) * | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| AR087973A1 (es) | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
-
2013
- 2013-05-27 TW TW102118698A patent/TWI513705B/zh not_active IP Right Cessation
- 2013-05-30 AR ARP130101904 patent/AR091216A1/es unknown
- 2013-06-05 AU AU2013274638A patent/AU2013274638A1/en not_active Abandoned
- 2013-06-05 HK HK15103818.7A patent/HK1203357A1/xx unknown
- 2013-06-05 ES ES13730733.6T patent/ES2644787T3/es active Active
- 2013-06-05 CA CA2871145A patent/CA2871145A1/en not_active Abandoned
- 2013-06-05 CN CN201380030788.4A patent/CN104394882B/zh not_active Expired - Fee Related
- 2013-06-05 IN IN2132MUN2014 patent/IN2014MN02132A/en unknown
- 2013-06-05 WO PCT/US2013/044190 patent/WO2013188181A1/en not_active Ceased
- 2013-06-05 KR KR20147034366A patent/KR20150006060A/ko not_active Abandoned
- 2013-06-05 MX MX2014015257A patent/MX2014015257A/es unknown
- 2013-06-05 US US13/910,149 patent/US8741841B2/en active Active
- 2013-06-05 EA EA201492053A patent/EA201492053A1/ru unknown
- 2013-06-05 SG SG11201408095XA patent/SG11201408095XA/en unknown
- 2013-06-05 PE PE2014002236A patent/PE20150201A1/es not_active Application Discontinuation
- 2013-06-05 BR BR112014029966A patent/BR112014029966A2/pt not_active IP Right Cessation
- 2013-06-05 JP JP2015517297A patent/JP6182600B2/ja active Active
- 2013-06-05 EP EP13730733.6A patent/EP2858662B1/en active Active
-
2014
- 2014-04-23 US US14/259,210 patent/US8927492B2/en active Active
- 2014-10-20 TN TN2014000439A patent/TN2014000439A1/fr unknown
- 2014-11-13 CL CL2014003078A patent/CL2014003078A1/es unknown
- 2014-11-20 IL IL235832A patent/IL235832A0/en unknown
- 2014-11-27 CO CO14261559A patent/CO7151525A2/es unknown
- 2014-12-10 PH PH12014502766A patent/PH12014502766A1/en unknown
- 2014-12-11 EC ECIEPI201430742A patent/ECSP14030742A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR091216A1 (es) | 2015-01-21 |
| CL2014003078A1 (es) | 2015-02-27 |
| WO2013188181A1 (en) | 2013-12-19 |
| CA2871145A1 (en) | 2013-12-19 |
| CN104394882A (zh) | 2015-03-04 |
| JP2015527974A (ja) | 2015-09-24 |
| US8741841B2 (en) | 2014-06-03 |
| US20140228282A1 (en) | 2014-08-14 |
| CN104394882B (zh) | 2016-06-22 |
| HK1203357A1 (en) | 2015-10-30 |
| EP2858662B1 (en) | 2017-08-09 |
| ECSP14030742A (es) | 2015-09-30 |
| MX2014015257A (es) | 2015-03-05 |
| JP6182600B2 (ja) | 2017-08-16 |
| TWI513705B (zh) | 2015-12-21 |
| EP2858662A1 (en) | 2015-04-15 |
| EA201492053A1 (ru) | 2015-02-27 |
| US8927492B2 (en) | 2015-01-06 |
| KR20150006060A (ko) | 2015-01-15 |
| US20130330336A1 (en) | 2013-12-12 |
| ES2644787T3 (es) | 2017-11-30 |
| PH12014502766A1 (en) | 2015-02-09 |
| PE20150201A1 (es) | 2015-02-19 |
| TN2014000439A1 (en) | 2016-03-30 |
| AU2013274638A1 (en) | 2014-11-06 |
| CO7151525A2 (es) | 2014-12-29 |
| SG11201408095XA (en) | 2015-01-29 |
| IL235832A0 (en) | 2015-01-29 |
| BR112014029966A2 (pt) | 2017-09-12 |
| TW201408693A (zh) | 2014-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02132A (OSRAM) | ||
| MX2014015258A (es) | Variantes del factor 21 de crecimiento de fibroblasto. | |
| TN2014000096A1 (en) | Fibroblast growth factor 21 variants | |
| TN2015000053A1 (en) | Fusion proteins for treating a metabolic syndrome | |
| MX2013005639A (es) | Metodos para el tratamiento de transtornos asociados con fgf21. | |
| PH12014502537A1 (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| TN2014000109A1 (en) | Fusion proteins for treating metabolic disorders | |
| MX2018005387A (es) | Variantes de fgf21. | |
| IN2014KN02830A (OSRAM) | ||
| MX2012006430A (es) | Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide. | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| IN2014DN09297A (OSRAM) | ||
| UA112981C2 (uk) | Варіант людського gdnf | |
| TN2013000211A1 (en) | Methods of treating fgf 21- associated disorders | |
| MA37640A1 (fr) | Protéines du facteur de croissance des fibroblastes 21 |